Kuros Biosciences AG (CSBTF)
USD 32.4
(3.09%)
USD 32.4
(3.09%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -13.72 Million CHF | 5.95% |
| 2022 | -14.59 Million CHF | -93.54% |
| 2021 | -7.54 Million CHF | 34.54% |
| 2020 | -11.52 Million CHF | -2.38% |
| 2019 | -11.25 Million CHF | 3.77% |
| 2018 | -11.69 Million CHF | 29.06% |
| 2017 | -16.48 Million CHF | 16.51% |
| 2016 | -19.74 Million CHF | -417.07% |
| 2015 | 6.22 Million CHF | 118.3% |
| 2014 | -34.02 Million CHF | -10.38% |
| 2013 | -30.82 Million CHF | -234.48% |
| 2012 | -9.21 Million CHF | 50.92% |
| 2011 | -18.77 Million CHF | -1191.54% |
| 2010 | -1.45 Million CHF | 94.14% |
| 2009 | -24.82 Million CHF | 4.55% |
| 2008 | -26 Million CHF | -278.31% |
| 2007 | -6.87 Million CHF | 80.1% |
| 2006 | -34.55 Million CHF | -21.32% |
| 2005 | -28.48 Million CHF | -19.41% |
| 2004 | -23.85 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -105.5 Thousand CHF | 98.78% |
| 2024 Q2 | -105.5 Thousand CHF | 0.0% |
| 2023 FY | -13.72 Million CHF | 5.95% |
| 2023 Q2 | -5.05 Million CHF | -100.0% |
| 2023 Q1 | -2.52 Million CHF | 76.81% |
| 2023 Q4 | -8.67 Million CHF | -100.0% |
| 2023 Q3 | -4.33 Million CHF | 14.14% |
| 2022 Q1 | -1.85 Million CHF | 75.13% |
| 2022 FY | -14.59 Million CHF | -93.54% |
| 2022 Q4 | -10.89 Million CHF | -100.0% |
| 2022 Q3 | -5.44 Million CHF | -47.18% |
| 2022 Q2 | -3.7 Million CHF | -100.0% |
| 2021 FY | -7.54 Million CHF | 34.54% |
| 2021 Q3 | -3.72 Million CHF | -3620.5% |
| 2021 Q4 | -7.44 Million CHF | -100.0% |
| 2021 Q2 | -100 Thousand CHF | -100.0% |
| 2021 Q1 | -50 Thousand CHF | 99.12% |
| 2020 Q3 | -2.84 Million CHF | 51.37% |
| 2020 Q4 | -5.68 Million CHF | -100.0% |
| 2020 Q2 | -5.84 Million CHF | -100.0% |
| 2020 FY | -11.52 Million CHF | -2.38% |
| 2020 Q1 | -2.92 Million CHF | 51.54% |
| 2019 Q3 | -3.01 Million CHF | 42.37% |
| 2019 FY | -11.25 Million CHF | 3.77% |
| 2019 Q4 | -6.02 Million CHF | -100.0% |
| 2019 Q2 | -5.22 Million CHF | -100.0% |
| 2019 Q1 | -2.61 Million CHF | 18.91% |
| 2018 Q4 | -3.22 Million CHF | 0.0% |
| 2018 Q2 | -2.62 Million CHF | 0.0% |
| 2018 Q3 | -3.22 Million CHF | -22.85% |
| 2018 FY | -11.69 Million CHF | 29.06% |
| 2018 Q1 | -2.62 Million CHF | 44.85% |
| 2017 Q1 | -3.48 Million CHF | -7.41% |
| 2017 Q2 | -3.48 Million CHF | 0.0% |
| 2017 Q3 | -4.75 Million CHF | -36.5% |
| 2017 Q4 | -4.75 Million CHF | 0.0% |
| 2017 FY | -16.48 Million CHF | 16.51% |
| 2016 Q1 | -6.62 Million CHF | -206.4% |
| 2016 Q2 | -6.62 Million CHF | 0.0% |
| 2016 FY | -19.74 Million CHF | -417.07% |
| 2016 Q3 | -3.24 Million CHF | 51.04% |
| 2016 Q4 | -3.24 Million CHF | 0.0% |
| 2015 Q1 | -729 Thousand CHF | 0.0% |
| 2015 Q4 | -2.16 Million CHF | 0.0% |
| 2015 FY | 6.22 Million CHF | 118.3% |
| 2015 Q2 | -729 Thousand CHF | 0.0% |
| 2015 Q3 | -2.16 Million CHF | -196.71% |
| 2014 FY | -34.02 Million CHF | -10.38% |
| 2013 Q4 | -9.69 Million CHF | -27.92% |
| 2013 Q2 | -8.14 Million CHF | -50.42% |
| 2013 Q1 | -5.41 Million CHF | -36.75% |
| 2013 Q3 | -7.57 Million CHF | 6.97% |
| 2013 FY | -30.82 Million CHF | -234.48% |
| 2012 Q2 | -2.61 Million CHF | -203.2% |
| 2012 Q4 | -3.95 Million CHF | 24.1% |
| 2012 Q3 | -5.21 Million CHF | -99.54% |
| 2012 Q1 | 2.53 Million CHF | 195.62% |
| 2012 FY | -9.21 Million CHF | 50.92% |
| 2011 Q4 | -2.64 Million CHF | 56.52% |
| 2011 Q2 | -4.72 Million CHF | 11.12% |
| 2011 Q1 | -5.31 Million CHF | 20.01% |
| 2011 Q3 | -6.09 Million CHF | -29.01% |
| 2011 FY | -18.77 Million CHF | -1191.54% |
| 2010 Q1 | -3.81 Million CHF | -212.29% |
| 2010 FY | -1.45 Million CHF | 94.14% |
| 2010 Q4 | -6.64 Million CHF | -10.62% |
| 2010 Q3 | -6 Million CHF | -140.01% |
| 2010 Q2 | 15 Million CHF | 493.57% |
| 2009 Q4 | -1.22 Million CHF | 78.33% |
| 2009 FY | -24.82 Million CHF | 4.55% |
| 2009 Q1 | -11.78 Million CHF | 0.0% |
| 2009 Q2 | -6.18 Million CHF | 47.49% |
| 2009 Q3 | -5.63 Million CHF | 8.92% |
| 2008 FY | -26 Million CHF | -278.31% |
| 2007 FY | -6.87 Million CHF | 80.1% |
| 2006 FY | -34.55 Million CHF | -21.32% |
| 2005 FY | -28.48 Million CHF | -19.41% |
| 2004 FY | -23.85 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Agentix Corp. | -1.37 Million USD | -898.9% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -96.582% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -332.832% |
| Biomind Labs Inc. | -1.21 Million USD | -1030.428% |
| ContraFect Corporation | -65.15 Million USD | 78.931% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -269.977% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -476.554% |
| CSL Limited | 2.64 Billion USD | 100.52% |
| CytoDyn Inc. | -49.84 Million USD | 72.458% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 125.91% |
| GB Sciences, Inc. | -1.36 Million USD | -908.095% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -604.22% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -353.615% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2070.596% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -5917.262% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 78.072% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3203.897% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -654.012% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1441.172% |
| Skye Bioscience, Inc. | -37.64 Million USD | 63.535% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 121.075% |
| SQZ Biotechnologies Company | -79.46 Million USD | 82.726% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -532.635% |
| Zenith Capital Corp. | -10.59 Million USD | -29.549% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 81.688% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -374.59% |
| Mesoblast Limited | -87.95 Million USD | 84.393% |
| Marizyme, Inc. | -65.34 Million USD | 78.994% |
| Genus plc | 7.9 Million USD | 273.759% |
| Pharming Group N.V. | -10.54 Million USD | -30.138% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -55.213% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -694.637% |
| IMV Inc. | -36.48 Million USD | 62.377% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -70.317% |
| MultiCell Technologies, Inc. | -380.07 USD | -3611603.107% |
| ONE Bio Corp. | 8.67 Million USD | 258.207% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 73.445% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -267.72% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -342.554% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -73.691% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -91559.989% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 13.511% |
| Alpha Cognition Inc. | -13.77 Million USD | 0.331% |
| Enzolytics Inc. | -2.17 Million USD | -530.595% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 95.348% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 14107.143% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 298.235% |
| Genscript Biotech Corporation | -95.47 Million USD | 85.623% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -108.74% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -4920.812% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -231.095% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -22611.551% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -584.599% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -26.031% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -180.942% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -266.403% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1199.835% |
| EV Biologics, Inc. | -1.26 Million USD | -983.311% |
| Q BioMed Inc. | -2.05 Million USD | -568.927% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -259.44% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 77.016% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | -61.818% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -135.97% |
| HST Global, Inc. | -146.21 Thousand USD | -9288.551% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -927.908% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -682.267% |
| Halberd Corporation | -79.67 Thousand USD | -17128.526% |
| Resverlogix Corp. | -3.61 Million USD | -280.249% |
| Cell Source, Inc. | -5.32 Million USD | -157.968% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -245.508% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.41 Million USD | -114.028% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -58961.182% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -187.827% |
| Kadimastem Ltd | -3.3 Million USD | -315.039% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -208.99% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -3010.096% |
| LadRx Corporation | 400.44 Thousand USD | 3527.954% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1441.172% |
| Affymax, Inc. | -14.42 Million USD | 4.832% |
| Itoco Inc. | -1.86 Million USD | -634.459% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -722.469% |
| Mobile Lads Corp. | -2.26 Million USD | -506.506% |
| International Stem Cell Corporation | -131 Thousand USD | -10378.626% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -4.28 Million USD | -220.724% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -17268.694% |
| Qrons Inc. | -789.34 Thousand USD | -1639.032% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1357.948% |
| SYBLEU INC | -180.3 Thousand USD | -7513.253% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -557.524% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1245.784% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -751.162% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -25192.969% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -442.516% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 71.445% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -549.338% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1657.873% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -333.302% |
| Neutra Corp. | -233.46 Thousand USD | -5779.682% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 32.349% |
| PureTech Health plc | -65.69 Million USD | 79.106% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 35.453% |
| IXICO plc | -1.17 Million USD | -1065.28% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -38.279% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 75.972% |
| CSL Limited | 2.64 Billion USD | 100.52% |
| Cellectis S.A. | -103.17 Million USD | 86.695% |